ateral Flow Assay for Detection of Through Tumor Necrosis Factor Alpha (Infliximab) levels
Completed
- Conditions
- Crohn's disease10017969
- Registration Number
- NL-OMON32551
- Lead Sponsor
- niversitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
Crohn's disease, infliximab therapy
Exclusion Criteria
None
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie lateral flow assay detection of Infliximab in Crohn's disease (NL-OMON32551)?
How does lateral flow assay for Infliximab compare to ELISA in monitoring TNF-alpha levels in Crohn's patients (NL-OMON32551)?
What biomarkers predict Infliximab response in Crohn's disease using lateral flow assay (NL-OMON32551)?
What adverse events are linked to TNF-alpha inhibition via Infliximab in NL-OMON32551 observational study?
Are alternative TNF inhibitors or combo therapies evaluated alongside Infliximab monitoring in NL-OMON32551?